Lieu Hsiao D 4

Accession 0001209191-23-054732

CIK 0001426332other

Filed

Nov 7, 7:00 PM ET

Accepted

Nov 8, 6:08 PM ET

Size

26.4 KB

Accession

0001209191-23-054732

Form 4

Period: 2023-11-06

SVP, Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−25,000→ 0 total
Exercise: $16.47Exp: 2030-02-03→ Common Stock (25,000 underlying)
Award
Stock Option (Right to Buy)
2023-11-06+100,000→ 100,000 total
Exercise: $0.84Exp: 2031-03-16→ Common Stock (100,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−190,000→ 0 total
Exercise: $12.06Exp: 2029-03-18→ Common Stock (190,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−100,000→ 0 total
Exercise: $31.93Exp: 2031-03-16→ Common Stock (100,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−150,000→ 0 total
Exercise: $15.20Exp: 2032-03-02→ Common Stock (150,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−150,000→ 0 total
Exercise: $5.36Exp: 2032-11-03→ Common Stock (150,000 underlying)
Award
Stock Option (Right to Buy)
2023-11-06+190,000→ 190,000 total
Exercise: $0.84Exp: 2029-03-18→ Common Stock (190,000 underlying)
Award
Stock Option (Right to Buy)
2023-11-06+150,000→ 150,000 total
Exercise: $0.84Exp: 2032-11-03→ Common Stock (150,000 underlying)
Award
Stock Option (Right to Buy)
2023-11-06+25,000→ 25,000 total
Exercise: $0.84Exp: 2030-02-03→ Common Stock (25,000 underlying)
Award
Stock Option (Right to Buy)
2023-11-06+150,000→ 150,000 total
Exercise: $0.84Exp: 2032-03-02→ Common Stock (150,000 underlying)

Footnotes (6)

[F1]Fully vested.
[F2]Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
[F3]The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.
[F4]The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
[F5]The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
[F6]The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.

Documents

1 file

NGM BIOPHARMACEUTICALS INC

CIK 0001426332

Entity typeother